Targeting CD123 appears to be a promising strategy in acute leukemias, as a CD3‐CD123 BiTE has also been developed for treating AML and may prove to be useful against high‐risk ALL.39 This evidence concerns the gene IL3RA and acute lymphoblastic leukemia.